{"id":15567,"date":"2022-03-08T00:00:00","date_gmt":"2022-03-08T00:00:00","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/agreement-for-antiviral-biologics-low-cost-production\/"},"modified":"2023-08-28T14:26:22","modified_gmt":"2023-08-28T14:26:22","slug":"agreement-for-antiviral-biologics-low-cost-production","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/","title":{"rendered":"Agreement for antiviral biologics low cost production"},"content":{"rendered":"\n

Good news from low-income countries around the world. Medicines Patent Pool (MPP) stated<\/a> that it had made a deal with several companies producing generic drugs, in order to get low cost antiviral medicines against SARS-CoV-2, the coronavirus responsible for COVID-19 pandemic, which is panicking the whole planet.<\/p>\n\n\n\n

Thanks to this, many Nations, not disposing of great economic means, will be able to get the medicines they need<\/a> to an affordable price and they will be able to efficaciously fight infections.<\/p>\n\n\n\n

Agreement with Merck<\/h2>\n\n\n\n

In particular, in October 2021, MPP subscribed a license deal with MSD, the society also known as Merck & Co., Inc, in countries other than Canada and USA, and residing in Kenilworth, NJ, USA.<\/p>\n\n\n\n

According to the deal, molnupiravir<\/strong>, the antiviral drug to treat COVID-19 that Merck is developing together with United biotech society Ridgeback Biotherapeutics (reseeding in Miami, Florida), is going to be produced by 27 specialized companies, at a modest price, and it is going to supply 105 developing countries<\/strong>.<\/strong><\/p>\n\n\n\n

The agreement<\/h2>\n\n\n\n

13 of theese 27 companies will produce both the raw materials needed for molnupiravir synthesis and the drug itself, when done and ready for delivery; while 5 of them will just produce the raw ingredients; and 9 will synthesize the medicine alone, without its precursors.<\/p>\n\n\n\n

Theese societies are situated in 11 countries: Bangladesh, China, Egypt\/Jordan, India, Indonesia, Kenya, Pakistan, South Africa, South Correa e Viet Nam.<\/p>\n\n\n\n

In order to be included in the agreement, the pharmas involved had to prove to be measured up for the quality requirements internationally requested and evaluated by Medicines Patent Pool only, which decided exclusively and independently.<\/p>\n\n\n\n

MSD, Ridgeback Biotherapeutics and Emory University, the athenaeum where molnupiravir was born, will not receive royalties from the sales of the drug.<\/p>\n\n\n\n

The Executive Director of MPP, Charles Gore<\/strong>, declared: \u201cThis is a crucial step to guarantee a global access to an urgent treatment against COVID-19 and we are confident that theese treatments will be quickly available in low-income countries. The producing companies are working in close contact with regulator authorities\u201d. I<\/p>\n\n\n\n

Even Paul Schaper<\/strong>, Executive Director, Global Public Policy, MSD, made a statement: \u201cwe are glad to see this dream coming true, with such a geographical diversity of the elected companies involved in the process\u201d.<\/p>\n","protected":false},"excerpt":{"rendered":"

The antiviral biologic molnupiravir is going to be synthesized in 27
\nspecialized companies for a modest amount of money, and it is going to
\nsupply 105 developing countries<\/p>\n","protected":false},"author":32,"featured_media":15771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[789],"tags":[],"class_list":{"0":"post-15567","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-deal-finance-en"},"yoast_head":"\nAgreement for antiviral biologics low cost production - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agreement for antiviral biologics low cost production - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-08T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-28T14:26:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"headline\":\"Agreement for antiviral biologics low cost production\",\"datePublished\":\"2022-03-08T00:00:00+00:00\",\"dateModified\":\"2023-08-28T14:26:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\"},\"wordCount\":378,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg\",\"articleSection\":[\"Deal & Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\",\"name\":\"Agreement for antiviral biologics low cost production - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg\",\"datePublished\":\"2022-03-08T00:00:00+00:00\",\"dateModified\":\"2023-08-28T14:26:22+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"description\":\"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg\",\"width\":1024,\"height\":683,\"caption\":\"agreement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agreement for antiviral biologics low cost production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agreement for antiviral biologics low cost production - MakingPharmaIndustry","description":"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/","og_locale":"en_US","og_type":"article","og_title":"Agreement for antiviral biologics low cost production - MakingPharmaIndustry","og_description":"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2022-03-08T00:00:00+00:00","article_modified_time":"2023-08-28T14:26:22+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg","type":"image\/jpeg"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"headline":"Agreement for antiviral biologics low cost production","datePublished":"2022-03-08T00:00:00+00:00","dateModified":"2023-08-28T14:26:22+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/"},"wordCount":378,"commentCount":0,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg","articleSection":["Deal & Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/","name":"Agreement for antiviral biologics low cost production - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg","datePublished":"2022-03-08T00:00:00+00:00","dateModified":"2023-08-28T14:26:22+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"description":"The antiviral biologic molnupiravir is going to be synthesized in 27specialized companies for a modest amount of money, and it is going tosupply 105 developing countries","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/antiviral.jpeg","width":1024,"height":683,"caption":"agreement"},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/deal-finance-en\/agreement-for-antiviral-biologics-low-cost-production\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Agreement for antiviral biologics low cost production"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=15567"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15567\/revisions"}],"predecessor-version":[{"id":16278,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15567\/revisions\/16278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/15771"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=15567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=15567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=15567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}